These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34213594)

  • 1. Proton Pump Inhibitors Inhibit PHOSPHO1 Activity and Matrix Mineralisation In Vitro.
    Staines KA; Myers K; Little K; Ralston SH; Farquharson C
    Calcif Tissue Int; 2021 Dec; 109(6):696-705. PubMed ID: 34213594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro inhibition of methadone and oxycodone cytochrome P450-dependent metabolism: reversible inhibition by H2-receptor agonists and proton-pump inhibitors.
    Moody DE; Liu F; Fang WB
    J Anal Toxicol; 2013 Oct; 37(8):476-85. PubMed ID: 23857299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Expression of PHOSPHO1, nSMase2 and TNAP is Coordinately Regulated by Continuous PTH Exposure in Mineralising Osteoblast Cultures.
    Houston DA; Myers K; MacRae VE; Staines KA; Farquharson C
    Calcif Tissue Int; 2016 Nov; 99(5):510-524. PubMed ID: 27444010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function: a unified model of the mechanisms of initiation of skeletal calcification.
    Yadav MC; Simão AM; Narisawa S; Huesa C; McKee MD; Farquharson C; Millán JL
    J Bone Miner Res; 2011 Feb; 26(2):286-97. PubMed ID: 20684022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison tables: H2-receptor antagonists and PPIs.
    Med Lett Drugs Ther; 2022 Apr; 64(1647):e56-e57. PubMed ID: 35348553
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3.
    Narumi K; Sato Y; Kobayashi M; Furugen A; Kasashi K; Yamada T; Teshima T; Iseki K
    Biopharm Drug Dispos; 2017 Dec; 38(9):501-508. PubMed ID: 28801980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Safety of proton pump inhibitors].
    Esplugues JV; Martí-Cabrera M; Ponce J
    Med Clin (Barc); 2006 Nov; 127(20):790-5. PubMed ID: 17198667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PHOSPHO1-A novel phosphatase specifically expressed at sites of mineralisation in bone and cartilage.
    Houston B; Stewart AJ; Farquharson C
    Bone; 2004 Apr; 34(4):629-37. PubMed ID: 15050893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ; Andersson TB; Ahlström M; Weidolf L
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of PHOSPHO1 activity results in impaired skeletal mineralization during limb development of the chick.
    Macrae VE; Davey MG; McTeir L; Narisawa S; Yadav MC; Millan JL; Farquharson C
    Bone; 2010 Apr; 46(4):1146-55. PubMed ID: 20053388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Proton Pump Inhibitors and Histamine Receptor 2 Antagonists on Blastocystis ST3 and Selected Microorganisms of Intestinal Microbiota In Vitro.
    Lepczyńska M; Dzika E; Chen W; Lu CY
    Clin Transl Gastroenterol; 2021 Apr; 12(4):e00325. PubMed ID: 33835078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant Administration of a Histamine2 Receptor Antagonist and Proton Pump Inhibitor Enhances Gastric Acid Suppression.
    Abdul-Hussein M; Freeman J; Castell D
    Pharmacotherapy; 2015 Dec; 35(12):1124-9. PubMed ID: 26621819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional involvement of PHOSPHO1 in matrix vesicle-mediated skeletal mineralization.
    Roberts S; Narisawa S; Harmey D; Millán JL; Farquharson C
    J Bone Miner Res; 2007 Apr; 22(4):617-27. PubMed ID: 17227223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of acid suppression in the hospital setting: focus on proton pump inhibition.
    Pisegna JR
    Crit Care Med; 2002 Jun; 30(6 Suppl):S356-61. PubMed ID: 12072661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pantoprazole increases cell viability and function of primary human osteoblasts in vitro.
    Prause M; Seeliger C; Unger M; van Griensven M; Haug AT
    Injury; 2014 Aug; 45(8):1156-64. PubMed ID: 24893920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet inhibitory effect of clopidogrel in patients treated with omeprazole, pantoprazole, and famotidine: a prospective, randomized, crossover study.
    Arbel Y; Birati EY; Finkelstein A; Halkin A; Kletzel H; Abramowitz Y; Berliner S; Deutsch V; Herz I; Keren G; Banai S
    Clin Cardiol; 2013 Jun; 36(6):342-6. PubMed ID: 23630016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials.
    Salas M; Ward A; Caro J
    BMC Gastroenterol; 2002 Jul; 2():17. PubMed ID: 12119060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ablation of osteopontin improves the skeletal phenotype of phospho1(-/-) mice.
    Yadav MC; Huesa C; Narisawa S; Hoylaerts MF; Moreau A; Farquharson C; Millán JL
    J Bone Miner Res; 2014 Nov; 29(11):2369-81. PubMed ID: 24825455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
    Abed MN; Alassaf FA; Jasim MHM; Alfahad M; Qazzaz ME
    Pharmacology; 2020; 105(11-12):645-651. PubMed ID: 32289807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.